Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Paclitaxel
  • Taxoids

abstract

  • At this dose and schedule, docetaxel demonstrates significant antitumor activity in patients with advanced NSCLC. Further investigations of this agent in NSCLC are indicated.

publication date

  • June 1994

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 7911159

Additional Document Info

start page

  • 1232

end page

  • 7

volume

  • 12

number

  • 6